Pharmaceutical success for Derwentside firm
A Derwentside company is launching trials of a new product that is expected to attract attention from the world’s major pharmaceutical companies.
BioToolomics Ltd was set up in 2006 by Dr Chad Zhang, the developer of chromatography technology that gave the company a world-leading position in the field of bioseparation, vital in the development of new drugs and treatments based on antibodies, vaccines and enzymes.
Dr Zhang said: “We have proved our technology now and are moving on to the next critical stage with this new product. “Our patented resin technology provides from fifty to a hundred times improvement in separation efficiency and, coupled with our advanced chromatography column design, gives exceptional reproducibility and scalability.
“These two factors mean that our new pre-packed columns can realistically be used as disposable products which is a huge advantage for development and production use in the pharmaceutical industry. We hope to bring the product to market within a year and, as this is a rapidly-expanding market, there is real potential for us here.”
BioToolomics will begin product trials in August and is looking at possible partnerships with the major pharmaceutical companies producing antibody-based drugs in order to introduce the new technology into large-scale manufacturing.
BioToolomics is available on 01207 585820 and at www.biotoolomics.com.
This was posted in Bdaily's Members' News section by Ruth Mitchell .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning National email for free.